Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Checkpoint kinase 1 (Chk1) is a key element in the DNA-damage response pathway that is required for maintaining genomic stability. To study the potential role of Chk1 in mammary tumorigenesis, we disrupted it using a Cre/loxP system. We showed that although Chk1 heterozygosity caused abnormal development of the mammary gland, it was not sufficient to induce tumorigenesis. Simultaneous deletion of one copy of p53 failed to rescue the developmental defects; however, it synergistically induced mammary tumor formation in Chk1+/−;MMTV-Cre animals with a median time to tumor latency of about 10 months. Chk1 deficiency caused a preponderance of abnormalities, including prolongation, multipolarity, misalignment, mitotic catastrophe and loss of spindle checkpoint, that are accompanied by reduced expression of several cell cycle regulators, including Mad2. On the other hand, we also showed that Chk1 deficiency inhibited mammary tumor formation in mice carrying a homozygous deletion of p53, uncovering a complex relationship between Chk1 and p53. Furthermore, inhibition of Chk1 with a specific inhibitor, SB-218078, or acute deletion of Chk1 using small hairpin RNA killed mammary tumor cells effectively. These data show that Chk1 is critical for maintaining genome integrity and serves as a double-edged sword for cancer: although its inhibition kills cancer cells, it also triggers tumorigenesis when favorable mutations are accumulated for cell growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell-cycle checkpoints and cancer
Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · cited 2×
“The majority of cancers are characterized by abnormalities of the cell cycle (Kastan and Bartek, 2004; Deng, 2006).”
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Self-citationLiu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625 · cited 11×
“Targeted disruption of Chk1 and p53 in mouse mammary epithelium Chk1 was disrupted in mammary tissue by crossing a mouse strain that carries a loxP-flanked exon 2 of Chk1 (Liu et al., 2000) with MMTV-Cre transgenic mice (Wagner et al.”
InfluentialSelf-citationRadiation-induced cell cycle arrest compromised by p21 deficiency
Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., & Hannon, G. J. (1995) · Nature · doi:10.1038/377552a0 · Cited by 1,242 · cited 1×
“Most commonly, G1/S checkpoint abrogation figures prominently in these abnormalities, primarily because of mutations in the broadly important tumor suppressor p53, which enforces the checkpoint through p21 (Harper et al., 1993; el-Deiry et al., 1993; Brugarolas et al., 1995; Deng et al., 1995).”
Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents
Xiao, Z., Chen, Z., Gunasekera, A. H., Sowin, T. J., Rosenberg, S. H., Fesik, S., & Zhang, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300229200 · Cited by 388 · cited 4×
“Why does the absence of p53 not rescue the developmental defects, but allows tumor formation associated with Chk1 deficiency? Previous investigations showed that Chk1 is an essential kinase involved in the regulation of G1/S and G2/M cell cycle checkpoints and in cytokinesis (Liu et al., 2000; Zhao et al., 2002; Xiao…”
Influential
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Gaillard, H., García-Muse, T., & Aguilera, A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3916 · Cited by 1,089
Roles of Chk1 in cell biology and cancer therapy
Zhang, Y., & Hunter, T. (2014) · International Journal of Cancer · doi:10.1002/ijc.28226 · Cited by 462
Lecona, E., & Fernandez-Capetillo, O. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0034-3 · Cited by 325
Sorensen, C. S., & Syljuasen, R. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr697 · Cited by 318
Checkpoint kinase 1 in DNA damage response and cell cycle regulation
Patil, M., Pabla, N., & Dong, Z. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1307-3 · Cited by 317
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 275
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Ma, C. X., Janetka, J. W., & Piwnica-Worms, H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.009 · Cited by 271
Illicit survival of cancer cells during polyploidization and depolyploidization
Vitale, I., Galluzzi, L., Senovilla, L., Criollo, A., Jemaà, M., Castedo, M., & Kroemer, G. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.145 · Cited by 159
Metadata
- Authors
- Fishler, T., Li, Y.-Y., Wang, R.-H., Kim, H.-S., Sengupta, K., Vassilopoulos, A., Lahusen, T., Xu, X., Lee, M.-H., Liu, Q., Elledge, S.-J., Ried, T., & Deng, C.-X.
- Venue
- Oncogene
- Published
- 2010-05-17
- Volume
- 29
- Issue
- 28
- Pages
- 4007-4017
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1986979664
- Cited by
- 48
- References
- 5
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.